Drug profile · INN
neratinib maleate
NERATINIB MALEATE
neratinib maleate (NERATINIB MALEATE) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with PUMA BIOTECHNOLOGY, INC.. Route of administration: oral. Current US regulatory status: approved.
Drug details — neratinib maleate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 22
- Data quality
- 0.89
Quick answer
neratinib maleate (NERATINIB MALEATE) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with PUMA BIOTECHNOLOGY, INC.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Receptor protein-tyrosine kinase erbB-2 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is neratinib maleate?
neratinib maleate (NERATINIB MALEATE) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with PUMA BIOTECHNOLOGY, INC.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for neratinib maleate?
NERATINIB MALEATE is a marketed brand name for neratinib maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of neratinib maleate?
neratinib maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.